aldosterone has been researched along with Muscular Dystrophy, Duchenne in 5 studies
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eplerenone treatment alone decreased a number of important muscle-specific genes." | 1.46 | Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle. ( Chadwick, JA; Gomez-Sanchez, CE; Gomez-Sanchez, EP; Hauck, JS; Rafael-Fortney, JA, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Howard, ZM | 1 |
| Rastogi, N | 1 |
| Lowe, J | 2 |
| Hauck, JS | 2 |
| Ingale, P | 1 |
| Gomatam, C | 1 |
| Gomez-Sanchez, CE | 3 |
| Gomez-Sanchez, EP | 3 |
| Bansal, SS | 1 |
| Rafael-Fortney, JA | 3 |
| Lindsay, A | 1 |
| Russell, AP | 1 |
| Chadwick, JA | 2 |
| Heier, CR | 1 |
| Yu, Q | 1 |
| Fiorillo, AA | 1 |
| Tully, CB | 1 |
| Tucker, A | 1 |
| Mazala, DA | 1 |
| Uaesoontrachoon, K | 1 |
| Srinivassane, S | 1 |
| Damsker, JM | 1 |
| Hoffman, EP | 1 |
| Nagaraju, K | 1 |
| Spurney, CF | 1 |
| Swager, SA | 1 |
| Welc, SS | 1 |
| Tidball, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)[NCT05185622] | Phase 2 | 54 participants (Anticipated) | Interventional | 2022-03-21 | Recruiting | ||
| A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy[NCT05166109] | Phase 2 | 39 participants (Anticipated) | Interventional | 2022-07-07 | Recruiting | ||
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
5 other studies available for aldosterone and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Myeloid mineralocorticoid receptors contribute to skeletal muscle repair in muscular dystrophy and acute muscle injury.
Topics: Aldosterone; Animals; Barium Compounds; Chlorides; Cytokines; Diaphragm; Disease Models, Animal; Fem | 2022 |
The unconditioned fear response in dystrophin-deficient mice is associated with adrenal and vascular function.
Topics: Aldosterone; Animals; Corticosterone; Dystrophin; Estradiol; Estrogens; Fear; Female; Humans; Male; | 2023 |
Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.
Topics: Adolescent; Adult; Aldosterone; Blotting, Western; Cells, Cultured; Eplerenone; Humans; Male; Muscle | 2017 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associ | 2019 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associ | 2019 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associ | 2019 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associ | 2019 |
Myeloid cells are capable of synthesizing aldosterone to exacerbate damage in muscular dystrophy.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Cytochrome P-450 CYP11B2; Disease | 2016 |